White Paper

**Abstract:**

Metformin, a medication commonly used to treat type 2 diabetes, has shown potential in preventing the onset of dementia. This report discusses the negative impact of dementia on society and the epidemiology of the disease, the background of metformin and its potential neuroprotective effects, and proposes the use of the medication as a solution to the problem of dementia. However, challenges and limitations to the use of metformin for the prevention of dementia are also discussed, including its potential effectiveness, safety in individuals without diabetes, and the need for further research. Overall, the use of metformin for the prevention of dementia should be part of a comprehensive approach to addressing the problem of dementia.

**Problem Statement:**

Dementia is a broad term used to describe a decline in cognitive function, including memory, language, and problem-solving abilities. This decline can have a significant negative impact on individuals, their families, and society as a whole. Dementia is a growing problem, with an estimated 47 million people living with the disease worldwide and this number expected to triple by 2050 [1].

Dementia is most commonly seen in older adults, with the risk of developing the disease increasing with age [1]. The most common cause of dementia is Alzheimer's disease, accounting for 60-70% of cases [1]. Other causes of dementia include vascular dementia, Lewy body dementia, and frontotemporal dementia [1].

The impact of dementia on individuals and society is significant. In addition to the cognitive decline, individuals with dementia may experience changes in behavior and personality and may require assistance with daily activities [1]. The burden on caregivers, often family members, can be significant and can lead to physical and emotional strain. The financial costs of dementia are also significant, with the global cost of dementia estimated to be over $1 trillion and an expected $2.8 trillion by 2030 [1].

**Background:**

Metformin is a medication that has been used for over 60 years to treat type 2 diabetes [2]. It works by lowering blood sugar levels and has been shown to be effective at improving insulin sensitivity and reducing the risk of complications associated with diabetes [3]. Recently, metformin has been studied for its potential in preventing the onset of dementia [4].

Some studies have suggested that metformin may have neuroprotective effects and may be able to prevent the development of Alzheimer's disease [4, 5]. The exact mechanism by which metformin may have these effects is not fully understood, but it is thought to involve the activation of AMP-activated protein kinase (AMPK), a protein that plays a role in regulating cellular metabolism [4]. Activation of AMPK has been shown to have protective effects on neurons, and may be able to prevent the development of neurodegenerative diseases such as Alzheimer's [6, 7].

In addition to its potential neuroprotective effects, metformin has several other properties that make it a potential candidate for the prevention of dementia. Metformin is a relatively safe medication, with a low risk of serious side effects. It is also widely available and is relatively inexpensive, making it a potentially attractive option for the prevention of dementia.

**Solution:**

The use of metformin as a potential preventative measure for dementia warrants further investigation. Large-scale clinical trials are needed to fully assess the effectiveness of the medication in preventing the onset of dementia. If metformin is found to be effective, it could provide a low-cost and widely available solution to the growing problem of dementia.

There are some challenges and limitations to consider when using metformin for the prevention of dementia. One potential challenge is that metformin may not be effective in all individuals. The neuroprotective effects of the medication may vary depending on factors such as age, genetic makeup, and the presence of other medical conditions. In addition, some individuals may not be able to take metformin due to side effects or other contraindications. Long-term use of metformin for the prevention of dementia has not yet been studied, and while the medication has been shown to be safe for use in individuals with type 2 diabetes, it has mainly been tested in this population, and therefore, its safety and effectiveness in individuals without diabetes is not well-established. Further research is needed to determine the potential risks and benefits of using metformin for the prevention of dementia in a broader population.

If metformin is found to be effective in preventing the onset of dementia, it is not a cure for the disease. Dementia is a complex and progressive condition, and no single existing medication or intervention is likely to be able to fully prevent or reverse its effects. The use of metformin, if found to be effective, should be seen as one component of a broader approach to addressing the problem of dementia.

**Conclusion:**

Dementia is a growing problem with significant negative impacts on individuals, families, and society. The use of metformin as a potential preventative measure for dementia warrants further investigation through clinical trials. If effective, metformin could provide a low-cost and widely available solution to the problem of dementia. However, there are challenges and limitations to consider, and the long-term effectiveness of the medication remains to be seen. Overall, the use of metformin for the prevention of dementia should be considered part of a comprehensive approach to addressing the problem of dementia.

**References:**

1. Greenblat C. (September 20, 2022). Dementia. World Health Organization, https://www.who.int/news-room/fact-sheets/detail/dementia

2. Lv, Z., & Guo, Y. (2020). Metformin and Its Benefits for Various Diseases. *Frontiers in endocrinology*, *11*, 191. https://doi.org/10.3389/fendo.2020.00191

3. Lin, Y., Wang, K., Ma, C., Wang, X., Gong, Z., Zhang, R., Zang, D., & Cheng, Y. (2018). Evaluation of Metformin on Cognitive Improvement in Patients With Non-dementia Vascular Cognitive Impairment and Abnormal Glucose Metabolism. *Frontiers in aging neuroscience*, *10*, 227. https://doi.org/10.3389/fnagi.2018.00227

4. Campbell, J. M., Stephenson, M. D., de Courten, B., Chapman, I., Bellman, S. M., & Aromataris, E. (2018). Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. *Journal of Alzheimer's disease : JAD*, *65*(4), 1225–1236. https://doi.org/10.3233/JAD-180263

5. Hsu, C. C., Wahlqvist, M. L., Lee, M. S., & Tsai, H. N. (2011). Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. *Journal of Alzheimer's disease : JAD*, *24*(3), 485–493. https://doi.org/10.3233/JAD-2011-101524

6. Xu, L., & Ash, J. D. (2016). The Role of AMPK Pathway in Neuroprotection. *Advances in experimental medicine and biology*, *854*, 425–430. https://doi.org/10.1007/978-3-319-17121-0\_56

7. Assefa, B. T., Tafere, G. G., Wondafrash, D. Z., & Gidey, M. T. (2020). The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence. *BioMed research international*, *2020*, 9895121. https://doi.org/10.1155/2020/9895121